Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Receptos to begin phase III part of RPC-1063 study in relapsing multiple sclerosis

Dec. 9, 2013

Edivoxetine does not meet endpoint in phase III studies in major depressive disorder

Dec. 9, 2013

Novel V1B receptor antagonists demonstrate activity in animal models of anxiety and depression

Dec. 9, 2013

Novel muscarinic M4 positive allosteric modulator for the treatment of Huntington's disease

Dec. 5, 2013

miRNA improves survival in a murine model of ALS

Dec. 5, 2013

Development of a potassium channel activator for the treatment of migraine

Dec. 5, 2013

Teva and Takeda announce Japanese agreement for glatiramer acetate

Dec. 4, 2013

Phase III studies of clonidine gel for painful diabetic neuropathy to begin next year

Dec. 4, 2013

SUVN-911 demonstrates antidepressant activity in vivo

Dec. 4, 2013

Forest Laboratories to acquire U.S. rights to Saphris

Dec. 3, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...